STAAR SURGICAL CO
STAANASDAQTrading Snapshot
- Day Range
- $22.46 β $22.87
- 52-Week Range
- $15.59 β $35.87
- Volume
- $2.93B
- Avg Volume
- $3.03B
- Shares Outstanding
- 49.8M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $239M
- Last Q Revenue
- $94M
- P/E Ratio
- 256.4
- P/S Ratio
- 3.0x
- EPS (TTM)
- $0.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.0%
Why Investors Own STAA
- βHigh-growth profile β revenue up +50.6% YoY with expanding US Equity exposure.
- βHealthy economics β 43% gross margin and 25% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
STAAR SURGICAL CO
STAAAbout STAAR SURGICAL CO
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
STAAR SURGICAL CO tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift STAA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
STAAR SURGICAL CO announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.